Immix Biopharma, Inc.
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors (NCT05840835) | Immix Biopharma, Inc. | 2023-02-03 |
Track Immix Biopharma, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.